Regulatory Watch
Jul 2026: PCAC meets July 23–24 to review 7 peptides (BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, Epitalon) for 503A eligibility — docket FDA-2025-N-6895 Jul 2026: FDA staff briefing docs: human evidence for BPC-157 and TB-500 is insufficient — the agency's own scientists weigh against 503A approval Jun 2026: STAT/AP/NPR: new PCAC panel stacked with peptide-industry-conflicted members ahead of the July vote Jun 2026: FDA sends ~25 more warning letters to telehealth firms over compounded GLP-1 marketing (net-impression claims) Jun 2026: ADA 2026: retatrutide (TRIUMPH-1) posts up to ~28% mean weight loss at 80 weeks — but the grey-market version is a different product Apr 2026: RECLASSIFICATION HAPPENS: FDA removes 12 peptides from Category 2 (April 15) — but "off Cat 2" is NOT "legal to compound" Apr 2026: First real BPC-157 human RCT begins recruiting (Phase 2, ~120 subjects, hamstring injury) — NCT07437547 Mar 2026: Semaglutide FAILS in early Alzheimer's (EVOKE/EVOKE+, The Lancet) — no cognitive benefit vs. placebo across ~3,800 patients Mar 2026: FDA warning letters to 7 "research use only" peptide sites (Pink Pony, Mile High, PekCura, Prime Sciences, Gram Peptides) Mar 2026: NPR covers peptide reclassification (March 26) — mainstream audience discovers peptide market Mar 2026: 29 days post-RFK announcement: FDA has STILL not published reclassification — no Federal Register notice, no updated list Mar 2026: SAFE Drugs Act filed as H.R. 6509 — bipartisan bill would ban RUO sales of compounds identical to FDA-approved drugs Mar 2026: PolitiFact publishes peptide safety fact-check — documents gap between marketing claims and published evidence Mar 2026: Hims & Hers vendor profile added — NYSE-listed telehealth company building peptide manufacturing in California Mar 2026: 30+ clinic websites publishing reclassification articles — all financially conflicted, none independent Mar 2026: BREAKING: Peptide Sciences shuts down operations (March 6) — largest grey-market vendor gone Mar 2026: Finnrick data: Peptide Sciences BPC-157 scored A, but retatrutide scored E with counterfeit flagged across 37 samples Mar 2026: MMM Online: 'Get ready for the peptides gold rush' — pharma trade media covers market explosion Mar 2026: Jay Campbell: 'Federal government has decided RUO peptide manufacturing can no longer sell injectable peptides' Mar 2026: Grips Intelligence: Peptide Sciences was doing $7.4M/month in sales before shutdown — market vacuum now open Mar 2026: All American Peptide owners plead guilty — $3M+ forfeitures. Tailor Made Compounding: $1.79M forfeiture. June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022 Jul 2026: PCAC meets July 23–24 to review 7 peptides (BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, Epitalon) for 503A eligibility — docket FDA-2025-N-6895 Jul 2026: FDA staff briefing docs: human evidence for BPC-157 and TB-500 is insufficient — the agency's own scientists weigh against 503A approval Jun 2026: STAT/AP/NPR: new PCAC panel stacked with peptide-industry-conflicted members ahead of the July vote Jun 2026: FDA sends ~25 more warning letters to telehealth firms over compounded GLP-1 marketing (net-impression claims) Jun 2026: ADA 2026: retatrutide (TRIUMPH-1) posts up to ~28% mean weight loss at 80 weeks — but the grey-market version is a different product Apr 2026: RECLASSIFICATION HAPPENS: FDA removes 12 peptides from Category 2 (April 15) — but "off Cat 2" is NOT "legal to compound" Apr 2026: First real BPC-157 human RCT begins recruiting (Phase 2, ~120 subjects, hamstring injury) — NCT07437547 Mar 2026: Semaglutide FAILS in early Alzheimer's (EVOKE/EVOKE+, The Lancet) — no cognitive benefit vs. placebo across ~3,800 patients Mar 2026: FDA warning letters to 7 "research use only" peptide sites (Pink Pony, Mile High, PekCura, Prime Sciences, Gram Peptides) Mar 2026: NPR covers peptide reclassification (March 26) — mainstream audience discovers peptide market Mar 2026: 29 days post-RFK announcement: FDA has STILL not published reclassification — no Federal Register notice, no updated list Mar 2026: SAFE Drugs Act filed as H.R. 6509 — bipartisan bill would ban RUO sales of compounds identical to FDA-approved drugs Mar 2026: PolitiFact publishes peptide safety fact-check — documents gap between marketing claims and published evidence Mar 2026: Hims & Hers vendor profile added — NYSE-listed telehealth company building peptide manufacturing in California Mar 2026: 30+ clinic websites publishing reclassification articles — all financially conflicted, none independent Mar 2026: BREAKING: Peptide Sciences shuts down operations (March 6) — largest grey-market vendor gone Mar 2026: Finnrick data: Peptide Sciences BPC-157 scored A, but retatrutide scored E with counterfeit flagged across 37 samples Mar 2026: MMM Online: 'Get ready for the peptides gold rush' — pharma trade media covers market explosion Mar 2026: Jay Campbell: 'Federal government has decided RUO peptide manufacturing can no longer sell injectable peptides' Mar 2026: Grips Intelligence: Peptide Sciences was doing $7.4M/month in sales before shutdown — market vacuum now open Mar 2026: All American Peptide owners plead guilty — $3M+ forfeitures. Tailor Made Compounding: $1.79M forfeiture. June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022

What You'll Get

Weekly Market Brief

Concise summary of regulatory developments, vendor news, and market movements.

Research Spotlights

New study breakdowns with context on what the research actually shows (and doesn't).

Vendor Alerts

Warning letters, quality issues, and supply chain disruptions you should know about.

Practical Guidance

Actionable recommendations based on evidence, not vendor marketing.

No Affiliate Links Newsletter contains zero affiliate links. Just information.
No Sponsored Content Every word is written by our editorial team.
Unsubscribe Anytime One click. No questions asked.